BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
0.740
+0.138 (22.88%)
Nov 21, 2024, 1:19 PM EST - Market open

BriaCell Therapeutics Income Statement

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Jul '24 Jul '24 Jul '23 Jul '22 Jul '21 Jul '20 2019 - 2015
Selling, General & Admin
6.656.658.517.584.961.54
Upgrade
Research & Development
26.6826.6814.767.712.022.4
Upgrade
Operating Expenses
33.3333.3323.2715.296.983.94
Upgrade
Operating Income
-33.33-33.33-23.27-15.29-6.98-3.94
Upgrade
Interest Expense
----0-0.08-0.03
Upgrade
Interest & Investment Income
0.290.290.890.140-
Upgrade
Earnings From Equity Investments
-0.11-0.11----
Upgrade
Currency Exchange Gain (Loss)
-0.03-0.03-0.04-0.03-2.18-0.01
Upgrade
Other Non Operating Income (Expenses)
28.2428.242.12-11.65-4.450.02
Upgrade
EBT Excluding Unusual Items
-4.93-4.93-20.3-26.84-13.67-3.96
Upgrade
Other Unusual Items
-----0.14-0.06
Upgrade
Pretax Income
-4.93-4.93-20.3-26.84-13.82-4.02
Upgrade
Earnings From Continuing Operations
-4.93-4.93-20.3-26.84-13.82-4.02
Upgrade
Minority Interest in Earnings
0.140.14----
Upgrade
Net Income
-4.79-4.79-20.3-26.84-13.82-4.02
Upgrade
Net Income to Common
-4.79-4.79-20.3-26.84-13.82-4.02
Upgrade
Shares Outstanding (Basic)
1616161551
Upgrade
Shares Outstanding (Diluted)
1616161551
Upgrade
Shares Change (YoY)
5.35%5.35%0.81%242.82%533.09%23.16%
Upgrade
EPS (Basic)
-0.29-0.29-1.30-1.73-3.06-5.64
Upgrade
EPS (Diluted)
-0.29-0.29-1.30-1.73-3.06-5.64
Upgrade
Free Cash Flow
-24.58-24.58-23.74-12.48-7.75-1.27
Upgrade
Free Cash Flow Per Share
-1.49-1.49-1.52-0.81-1.71-1.77
Upgrade
EBITDA
-33.25-33.25-23.26-15.27-6.96-3.92
Upgrade
D&A For EBITDA
0.080.080.020.020.020.02
Upgrade
EBIT
-33.33-33.33-23.27-15.29-6.98-3.94
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.